Oliver LythAssociate at M VenturesSpeaker
Profile
Oliver Lyth joined M Ventures in 2024 and is currently an Associate in the Biotechnology investment team. Oliver leads diligence activities on prospective therapeutics investment opportunities and supports five M Ventures’ portfolio companies as Board Director (TwoStep Therapeutics) and Board Observer (Storm Therapeutics, iOnctura, Repronovo, and Future Fertility). Before joining M Ventures, Oliver acted as an Analyst in the due diligence team supporting LifeArc Ventures before joining IP Group’s Life Sciences Partnership as an Investment Manager. Oliver has an MBiochem from the University of Oxford and completed his PhD in Molecular Parasitology at Imperial College.
Agenda Sessions
Scaling Women's Health: Investment, Consolidation, and the Path Forward
, 13:15View Session
